Skip to content

Effect of a pharmacist-led multifaceted intervention on treatment outcomes in hypertensive patients: a cluster randomised clinical trial

Effect of a pharmacist-led multifaceted intervention on treatment outcomes in hypertensive patients: a cluster randomised clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400088844
Enrollment
Unknown
Registered
2024-08-27
Start date
2024-09-01
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Intervention group:pharmacist-led multifaceted intervention
Control group:conventional hypertension health education

Sponsors

First Affiliated Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) age 18-80 years; (2) patients with hypertension (diagnostic criteria: defined as systolic blood pressure = 140 mmHg or diastolic blood pressure = 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control; (3) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently; (4) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up; (5) permanent residents of the city where the center is located; (6) voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician; (2) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers; (3) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.; (4) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.

Design outcomes

Primary

MeasureTime frame
Blood pressure control rate;Time in target range (TTR);Medication Adherence;Cardiovascular events and all-cause death;

Secondary

MeasureTime frame
Mean systolic and diastolic pressure changes;Medication Appropriateness Index (MAI);Body Mass Index (BMI);Alcohol consumption;Nicotine consumption;Medication Adherence;Hypertension-related adverse events rate;

Countries

China

Contacts

Public ContactJingwen Wang

First Affiliated Hospital of Air Force Medical University

wangjingwen8021@163.com+86 29 8477 5475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026